Elan’s Alzheimer drug trial data due

ELAN could publish Phase II trial data on its leading Alzheimer’s test treatment — currently going under the catalogue name, AAB-001 — as soon as next week.

The Dublin and Athlone-based pharmaceutical company is working on a number of Alzheimer’s treatments, at various trial stages. AAB-001 — which is being co-developed by Wyeth — has, for a long time now, been its most developed treatment for this condition, and expectations for the vital Phase II trial results are relatively positive.

“We expect that the upcoming data will demonstrate that the drug is safe and well tolerated with no change in the side effect profile noted in the Phase I trial. On efficacy, given the relatively small number of patients in the trial, significant differences between treatment and placebo patients in overall cognition and functional parameters are extremely unlikely,” said Ian Hunter of Goodbody Stockbrokers.